Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07762937
Neurodynamic Tensioning Plus Grip Strengthening for Hand Grip StrengthTokat Gaziosmanpasa UniversityNot Yet RecruitingNot Applicable
NCT07762937Not Yet Recruiting
Not Applicable
Neurodynamic Tensioning Plus Grip Strengthening for Hand Grip StrengthTokat Gaziosmanpasa Unive...
NCT07763483
Do Endocrine Disruptors Accumulate in Children Undergoing Paediatric Dialysis?Hospices Civils de LyonNot Yet Recruiting
NCT07763483Not Yet Recruiting
—
Do Endocrine Disruptors Accumulate in Children Undergoing Paediatric Dialysis?Hospices Civils de Lyon
NCT07763327
Effects of a Wearable Device ,Phone App and Exercise on Cervico-thoracic Posture in University Students.Riphah International UniversityNot Yet RecruitingNot Applicable
NCT07763327Not Yet Recruiting
Not Applicable
Effects of a Wearable Device ,Phone App and Exercise on Cervico-thoracic Posture...Riphah International Univ...
NCT07764133
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian CancerUniversity of Tennessee Graduate School of MedicineRecruiting
NCT07764133Recruiting
—
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation a...University of Tennessee G...
NCT07764315
EEG-Based Decision-Support Algorithm for Hypoxic-Ischemic Encephalopathy in Term NewbornsAssistance Publique - Hôpitaux de ParisNot Yet Recruiting
NCT07764315Not Yet Recruiting
—
EEG-Based Decision-Support Algorithm for Hypoxic-Ischemic Encephalopathy in Term...Assistance Publique - Hôp...
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07762924
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryFudan UniversityRecruitingPhase 2
NCT07762924Recruiting
Phase 2
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Fol...Fudan University
NCT07762547
Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.Beijing Tiantan HospitalNot Yet RecruitingNot Applicable
NCT07762547Not Yet Recruiting
Not Applicable
Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moy...Beijing Tiantan Hospital
NCT07762313
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.Humacyte, Inc.Not Yet RecruitingPhase 3
NCT07762313Not Yet Recruiting
Phase 3
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular...Humacyte, Inc.
NCT07762911
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)University Hospital, Basel, SwitzerlandRecruitingNot Applicable
NCT07762911Recruiting
Not Applicable
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year...University Hospital, Base...
NCT07763093
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Class I Gingival RecessionUniversity of Medicine and Pharmacy at Ho Chi Minh CityActive Not RecruitingNot Applicable
NCT07763093Active Not Recruiting
Not Applicable
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Cla...University of Medicine an...
NCT07762469
Diagnostic Performance of a Flexible Penile Monitoring System for EDBin XuNot Yet Recruiting
NCT07762469Not Yet Recruiting
—
Diagnostic Performance of a Flexible Penile Monitoring System for EDBin Xu
NCT07763548
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Minimize Propofol Injection PainErasme University HospitalNot Yet RecruitingPhase 4
NCT07763548Not Yet Recruiting
Phase 4
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Mini...Erasme University Hospita...
NCT07762079
A Study of Engagement in the "Résonance(s)" Musical and Experiential Immersion Program Among Patients With Mental Disorders - IRISFederation Regionale de Recherche en Psychiatrie et Sante Mentale OccitanieNot Yet RecruitingNot Applicable
NCT07762079Not Yet Recruiting
Not Applicable
A Study of Engagement in the "Résonance(s)" Musical and Experiential Immersion P...Federation Regionale de R...
NCT07762430
Food Noise Survey Development and Validation in Hindi and English-Speaking AdultsDiabetes Foundation, IndiaNot Yet Recruiting
NCT07762430Not Yet Recruiting
—
Food Noise Survey Development and Validation in Hindi and English-Speaking Adult...Diabetes Foundation, Indi...
NCT07762963
Turkish Validation of the Core Life Activities ScaleTokat Gaziosmanpasa UniversityNot Yet Recruiting
NCT07762963Not Yet Recruiting
—
Turkish Validation of the Core Life Activities ScaleTokat Gaziosmanpasa Unive...
NCT07762989
Donor Ankle Sensorimotor Recovery After ACL Reconstruction With a Peroneus Longus Tendon AutograftGazi UniversityNot Yet Recruiting
NCT07762989Not Yet Recruiting
—
Donor Ankle Sensorimotor Recovery After ACL Reconstruction With a Peroneus Longu...Gazi University
NCT07762378
Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic TherapyInstituto de Investigación Sanitaria Gregorio MarañónNot Yet RecruitingNot Applicable
NCT07762378Not Yet Recruiting
Not Applicable
Clinical Impact of a Machine Learning Decision Support System for Empirical Anti...Instituto de Investigació...
NCT07762716
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762716Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTr...BreakBio Corp
Result Breakdown
Not yet recruiting14 (70%)
Recruiting3 (15%)
Completed1 (5%)
Unknown1 (5%)
Active, not recruiting1 (5%)
not_applicable8 (40%)
Not Specified8 (40%)
Phase 21 (5%)
Phase 31 (5%)
Phase 41 (5%)
Phase 11 (5%)